Videos
Clinical Conversations by Experts
View all

Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer
- Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6
- Tumor Board Reviewing PSMA PET in the Care of Patient with Gleason 4+4=8 GG 4, 6 Cores on Left, Gleason 4+3=7 GG, 6 Cores on Right Prostate Adenocarcinoma, Session 1 Case 4 - H Jacene, A Kibel, P Nguyen & A Morgans View all Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer videos

Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer
- Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore
- The Association Between the Time Interval Between Sequential Treatment With Radium-223 Therapy and 177Lu-PSMA in the RALU Study - Kambiz Rahbar
- Sequencing Radiopharmaceuticals: Efficacy and Safety Data of Radium-223 Followed by Lutetium-177-PSMA in the RALU Study - Oliver Sartor
- Radiopharmaceuticals in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans View all Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer videos

AUA 2023
- Alkaline Water: “Help or Hype” for Uric Acid Stone Patients - Paul Piedras
- Fluid Temperature Effect on Superpulse Thulium Fiber Laser Stone Ablation - Andrei D. Cumpanas
- The Application of Artificial Intelligence for Renal Stone Volume Determination: Ready for Prime Time? - Andrei D. Cumpanas View all AUA 2023 videos

Artificial Intelligence in Prostate Cancer 2022
- Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng
- Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model - Jonathan Tward
- Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer - Daniel Spratt View all Artificial Intelligence in Prostate Cancer 2022 videos
Featured Videos

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
Prostate cancer genomic classifier Videos
Latest Videos
Bladder Cancer Videos

DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt

A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
PCF 2022
Recent Conference Coverage
Conference Highlights Written by Physician-Scientist

AUA 2023 Conference Highlights
- AUA 2023: Optimal Management of cN+ Muscle Invasive Bladder Cancer
- AUA 2023: Intermediate Risk NMIBC: Surveillance and Treatment Challenges
- AUA 2023: Perioperative Outcomes of Radical Cystectomy Following Neoadjuvant Gemcitabine, Cisplatin and Atezolizumab

AUA 2023 Annual Urology Advocacy Summit Conference Highlights
- AUA Urology Advocacy Summit 2023: Need to Know: Inflation Reduction Act of 2022 and its Impact on Urology
- AUA Urology Advocacy Summit 2023: State Advocacy: Chaperone Rules and Criminalization of Physician Care
- AUA Urology Advocacy Summit 2023: Breaking Down Barriers to PSA Screenings
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles

Advanced Prostate Cancer
- PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations: Will This Be The Future of mCRPC First-Line Therapy?
Written by Rashid K. Sayyid, MD MSc & Zachary Klaassen, MD MSc
- Artificial Intelligence and Prostate Cancer: Risk Stratification After Primary Therapy, ADT Treatment Intensification, and Evaluation of Metastatic Disease
Written by Zachary Klaassen, MD, MSc and Rashid K. Sayyid, MD, MSc

mHSPC
- Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous Low Volume mHSPC
Written by Rashid K. Sayyid, MD MSc and Zachary Klaassen, MD MSc
- Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC
Written by Rashid K. Sayyid, MD MSc and Zachary Klaassen, MD,MSc
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Bladder Cancer Detection
Clinical Data Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC
Photocure ASA, The Bladder Cancer Company, announces the publication of the study “The Impact of Blue Light Cystoscopy Use Among Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence”. The article was published online 28 April 2023 in the peer-reviewed medical journal Clinical Genitourinary Cancer.
Reno, Nevada (UroToday.com) -- In February 2023, clinical data from the Veterans Affairs (VA) BRAVO study was presented at the ASCO Genitourinary Cancers Symposium in San Francisco, USA. The data demonstrated a significant decrease in the risk of recurrence and prolonged time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone. Read More
Reno, Nevada (UroToday.com) -- In February 2023, clinical data from the Veterans Affairs (VA) BRAVO study was presented at the ASCO Genitourinary Cancers Symposium in San Francisco, USA. The data demonstrated a significant decrease in the risk of recurrence and prolonged time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone. Read More
Clinical Application And Utility Of PYLARIFY
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain. Read More
ARAMIS Trial
Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Context: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit. Read More
ARASENS Trial
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.
Read More
Read More
VISION Trial
FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting. Read More